VericelVCEL +7.76%81 FCF Margin % is 22.11% as of Mar. 2026, which is 2848% above its 10-year median of 0.75. GuruFocus rates VCEL with a GF Score™ of 81/100 and a GF Value™ of $54.29 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Vericel ranks better than 87.07% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vericel's Free Cash Flow for the
three
months ended in Mar. 2026 was $15.1 Mil. Vericel's Revenue for the
three
months ended in Mar. 2026 was $68.4 Mil. Therefore, Vericel's FCF Margin % for the quarter that ended in Mar. 2026 was 22.11%.
The historical rank and industry rank for Vericel's FCF Margin % or its related term are showing as below:
VCEL'
s FCF Margin % Range Over the Past 10 Years
Min: -39.18 Med: 0.75 Max: 16.26
Current: 16.26
During the past 13 years, the highest FCF Margin % of Vericel was 16.26%. The lowest was -39.18%. And the median was 0.75%.
VCEL's FCF Margin % is ranked better than 87.07% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs VCEL: 16.26
Vericel FCF Margin % Related Terms
Vericel FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vericel's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vericel's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vericel's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a FCF Margin % of 22.11% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vericel and its competitors. This is 2848% above median its historical median of 0.75. According to the industry distribution chart, Vericel ranks #124 out of 959 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Vericel's FCF Margin % too high?
Vericel's current FCF Margin % of 22.11% is 2848% above median its 10-year median of 0.75. Based on the distribution chart, Vericel ranks #124 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vericel has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's FCF Margin % compare to PVLA and TSHA?
According to the Biotechnology industry distribution chart, Vericel ranks #124 out of 959 companies for FCF Margin %. This places Vericel in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vericel and its competitors. Vericel's current FCF Margin % is 22.11%, which is 2848% above median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $54.29, compared to a current price of $46.23 — trading 14.8% below its estimated fair value. The current FCF Margin % is 22.11%, which is 2848% above median its 10-year median of 0.75. Vericel's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vericel (VCEL), the current FCF Margin % is 22.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $46.23 is trading 14.8% below its estimated GF Value™ of $54.29.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
FCF Margin %: 22.11% (2848% above median its 10-year median of 0.75)
GF Value™: $54.29 vs. price of $46.23 (14.8% below fair value)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score
Get the complete analysis for VCEL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
